Protara Therapeutics (NASDAQ:TARA) Releases Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Protara Therapeutics (NASDAQ:TARA) announced its quarterly earnings data on Wednesday. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.09, Zacks reports.

Protara Therapeutics Trading Up 3.6 %

Protara Therapeutics stock traded up $0.12 during midday trading on Wednesday, reaching $3.48. The company’s stock had a trading volume of 7,203 shares, compared to its average volume of 311,389. Protara Therapeutics has a 52 week low of $1.60 and a 52 week high of $10.48. The business has a 50-day moving average price of $4.66 and a 200-day moving average price of $3.39. The stock has a market cap of $71.79 million, a PE ratio of -1.23 and a beta of 1.63.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on TARA shares. Guggenheim reiterated a “buy” rating and issued a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Friday, December 6th.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.